Aoyang Technology

Total investments

2

Average round size

7M

Portfolio companies

1

Rounds per year

0.10

Follow on index

0.50

Areas of investment
BiotechnologyInformation Technology

Summary

Aoyang Technology appeared to be the Corporate Investor, which was created in 2001. The main office of represented Corporate Investor is situated in the Zhangjiagang. The fund was located in Asia if to be more exact in China.

The typical case for the fund is to invest in rounds with 3 participants. Despite the Aoyang Technology, startups are often financed by Huasheng Capital, Highlight Capital. The meaningful sponsors for the fund in investment in the same round are Principle Capital, Jindi Commercial, Huasheng Capital. In the next rounds fund is usually obtained by Principle Capital, Jindi Commercial.

Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in less than 2 deals per year. The important activity for fund was in 2016.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Among the most popular portfolio startups of the fund, we may highlight Genechem (China). Besides, a startup requires to be at the age of 11-15 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Information Technology.

Show more

Investments analytics

Analytics

Total investments
2
Lead investments
0
Rounds per year
0.10
Follow on index
0.50
Investments by industry
  • Information Technology (2)
  • Biotechnology (2)
Investments by region
  • China (2)
Peak activity year
2019

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
19
Group Appearance index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Genechem (China) 05 Jan 2016 Biotechnology, Information Technology Early Stage Venture 15M China, Shanghai
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.